• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca has acquired Almirall’s respiratory business

AstraZeneca has acquired Almirall’s respiratory business

November 5, 2014
CenterWatch Staff

Almirall, a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances, has completed the transaction to transfer to AstraZeneca the rights to Almirall's respiratory franchise after all closing conditions have been satisfied. AZ now will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.

The franchise includes Eklira; Duaklir, the combination of aclidinium with formoterol (LAMA/LABA) that has received a positive opinion from the CHMP in the E.U. and is being developed in the U.S.; LAS100977, a once-daily long-acting beta2-agonist (LABA) in phase II development; an M3 antagonist beta2-agonist (MABA) platform in preclinical development (LAS191351, LAS194871) and phase I development (LAS190792); and multiple preclinical programs.

Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, also transfers to AZ. Additionally, 719 Almirall employees will transfer to AZ. 

Almirall in July announced the strategic transaction, which includes an upfront cash consideration upon completion of $875 million and up to $1.22 billion related to development, launch and sales-related milestones. AZ also has agreed to make various sales-related payments.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing